Ayush Ministry Issues Covid-19 Guidelines For Ayurveda And Unani Practitioners

Mumbai, 28 April 2021: The Union Ministry of Ayush has released revised guidelines for Ayurveda and Unani practitioners for Covid-19 patients in home isolation and Ayurveda and Unani preventive measures for self-care.

“It is aimed to increase awareness among the citizens regarding the effective home care solutions and recommended Ayush practices, to help them to enhance their immunity along with standard guideline for Ayurveda & Unani practitioners for management of prophylactic, asymptomatic and mild cases of Covid-19 during home isolation,” the ministry said.

These guidelines and advisories were developed through an extensive consultative process by the empowered committee within the interdisciplinary Ayush Research and Development Task Force setup by Union Ministry of Ayush.

The ministry said the Project Monitoring Unit for Covid-19 Studies, Central Council for Research in Ayurvedic Sciences (CCRAS), Central Council for Research in Unani Medicine (CCRUM), All India Institute of Ayurveda (AIIA) and National Medicinal Plant Board (NMPB) of this Ministry worked on formulating the advisories and guidelines.

The present guidelines and self-care measures provide clear guidance to Ayurveda & Unani practitioners regarding treatment of Covid-19 patients in different conditions of infection. This brings in uniformity and consistency in the Ayush-based responses to the pandemic across the country. It also helps state/UT governments to plan and incorporate these solutions into the Covid-19 management activities being deployed on the ground. Furthermore, these measures and guidelines contribute to the mainstreaming of Ayush solutions for the management of Covid-19, and will be immensely beneficial to the public since these solutions are easily accessible and will help to alleviate the hardships brought in by the pandemic.

The Ayush ministry issued an advisory on January 29, 2020 on how to protect oneself from Covid-19 and how to stay healthy. In this context, the ministry has also promoted the use of ready-made formulation like AyushKwath (Ayurveda) which is a simple admixture of four herbal ingredients which are well known in India and outside India for their immunomodulatory and anti-viral activities along with several other health benefits.

It added that keeping a note on the present public health challenges due to the second wave of Covid-19 pandemic, there is a requirement to urgently disseminate information about the guidelines for Ayurveda and Unani practitioners for the management of Covid-19 patients during home isolation.

“The effective evidence-based Ayurveda and Unani formulations/measures such as Ayush-64, Ashwagandha tablets, etc. have been included for the management of asymptomatic and mild cases of Covid-19 during home isolation,” it said.

  • Related Posts

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

    Pak-made illegal cosmetics recovered from Itwari shop

    Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert